Format

Send to

Choose Destination
Blood. 2017 May 11;129(19):2702-2705. doi: 10.1182/blood-2017-01-761973. Epub 2017 Mar 21.

Venetoclax and obinutuzumab in chronic lymphocytic leukemia.

Author information

1
Department I of Internal Medicine, Center of Integrated Oncology Cologne-Bonn, University Hospital Cologne, Cologne, Germany.
2
F. Hoffmann-La Roche Ltd, Welwyn Garden City, United Kingdom.
3
Moores Cancer Center, University of California San Diego, San Diego, CA.
4
Wellington Blood and Cancer Centre, Capital and Coast District Health Board, Wellington, New Zealand.
5
Malaghan Institute of Medical Research, Wellington, New Zealand.
6
Department of Pathology and Molecular Medicine, University of Otago Wellington, Wellington, New Zealand.
7
Queen Elizabeth II Health Science Center, Halifax, NS, Canada.
8
Department of Internal Medicine III, University Hospital Ludwig-Maximilians University Munich, Munich, Germany.
9
Monash Hematology, Monash University, Clayton, VIC, Australia.
10
Department of Hematology, Tom Baker Cancer Centre, Calgary, AB, Canada.
11
Hospital Ramon y Cajal, Madrid, Spain.
12
AbbVie, Inc., North Chicago, IL.
13
Department of Internal Medicine III, Ulm University, Ulm, Germany.
14
Department of Hematology, Oncology, Immunology, Palliative Care, Infectious Diseases and Tropical Medicine, Klinikum Schwabing, Munich, Germany.
15
Department of Immunology, Laboratory for Medical Immunology, Erasmus Medical Center, Rotterdam, Netherlands.
16
Second Department of Medicine, University Hospital of Schleswig-Holstein, Campus Kiel, Kiel, Germany; and.
17
Genentech, South San Francisco, CA.
PMID:
28325865
PMCID:
PMC5437733
DOI:
10.1182/blood-2017-01-761973
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for HighWire Icon for PubMed Central
Loading ...
Support Center